Horizon Discovery™ Group plc announced the appointment of Dr. Susan Galbraith, Senior Vice President and Head of Oncology Innovative Medicines at AstraZeneca, and Susan Searle, co-founder and ex-CEO of Imperial Innovations Group plc, as Non-Executive Directors on the Company's Board. Both join Horizon with immediate effect. Susan was previously at Bristol-Myers Squibb, where she was Vice President of Oncology and Clinical Biomarkers from 2008 to 2010.

Susan Searle has over 20 years' commercial experience as an entrepreneur and innovator.